Plehn, Jonathan F.

Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease

Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine

Hemoglobinopathies and Related DisordersPulmonary Hypertension Research and Treatments

Cited by 1,325

Reduction of Stroke Incidence After Myocardial Infarction With Pravastatin: The Cholesterol and Recurrent Events (CARE) Study

Plehn, J. F., Davis, B. R., Sacks, F. M., Rouleau, J. L., Pfeffer, M. A., Bernstein, V., Cuddy, T. E., Moyé, L. A., Piller, L. B., Rutherford, J., et al. (1999) · Circulation

Lipoproteins and Cardiovascular HealthAcute Ischemic Stroke Management

Cited by 429

Is There a Relationship between Exercise Systolic Blood Pressure Response and Left Ventricular Mass?: The Framingham Heart Study

Lauer, M. S., Levy, D., Anderson, K. M., & Plehn, J. F. (1992) · Annals of Internal Medicine

Cardiovascular Effects of ExerciseBlood Pressure and Hypertension Studies

Cited by 212

Exercise Blood Pressure and the Risk of Incident Cardiovascular Disease (from the Framingham Heart Study)

Lewis, G. D., Gona, P., Larson, M. G., Plehn, J. F., Benjamin, E. J., O'Donnell, C. J., Levy, D., Vasan, R. S., & Wang, T. J. (2008) · The American Journal of Cardiology

Cardiovascular and exercise physiologyCardiovascular Health and Disease Prevention

Cited by 133

Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST])

Carson, P., Fiuzat, M., O'Connor, C., Anand, I., Plehn, J., Lindenfeld, J. A., Silver, M., White, M., Miller, A., Davis, G., et al. (2010) · American Heart Journal

Heart Failure Treatment and ManagementStatistical Methods in Clinical Trials

Cited by 31